Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2'-Fucosyllactose (2'-FL) is a fucosylated neutral trisaccharide composed of L-fucose, D-galactose, and D-glucose units. It is the most prevalent human milk oligosaccharide (HMO), naturally present in human breast milk and making up about 30% of all HMOs[4]. It is produced commercially via microbial fermentation using E. coli or by chemical/enzymatic synthesis[4][8][6]. As a prebiotic compound, it promotes the growth of beneficial bifidobacteria in the gut and helps protect against infectious diseases by preventing pathogen adhesion to epithelial cells[4]. In addition to its prebiotic effects, studies suggest anti-inflammatory properties and potential immune-enhancing effects through modulation of cytokine production such as IL-10 and IFN-gamma[1][5]. Clinical trials are investigating its use as a dietary supplement for conditions like inflammatory bowel disease (IBD)[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2'-fucosyllactose.